Core Insights - Plus Therapeutics, Inc. has appointed Michael Rosol, Ph.D., as Chief Development Officer to lead clinical, pre-clinical, and biomarker development activities as the company transitions from mid-stage to pivotal trials in 2026 [1][2] - Dr. Rosol brings 25 years of experience in clinical trial design and operations, having previously served as Chief Medical Officer at Navidea Biopharmaceuticals and held key roles at Novartis Pharmaceuticals [2][3] - The company is focused on developing targeted radiotherapeutics for central nervous system cancers, specifically recurrent glioblastoma (GBM) and leptomeningeal metastases (LM), which currently lack FDA-approved therapies [5] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics aimed at enhancing clinical outcomes for patients with difficult-to-treat CNS cancers [5] - The company utilizes image-guided local beta radiation and targeted drug delivery approaches, with a pipeline that includes lead programs in recurrent GBM and LM [5] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [5] Disease Context - Leptomeningeal metastases (LM) occur in approximately 5% of cancer patients and are often terminal, with a one-year survival rate of only 7% [3] - Glioblastoma (GBM) affects around 15,000 patients annually in the U.S., with an average life expectancy of less than 24 months and a one-year survival rate of 40% [4] - There are currently no FDA-approved treatments for recurrent GBM that significantly extend patient life, highlighting a critical need for effective therapies [4]
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer